[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354281-105":59,"doc-detail-354281-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","patient-specific-3d-printed-hdr-surface-brachytherapy-for-basal-cell-carcinoma-in-older-patients-prospective-feasibility-and-imaging-response","Patient-specific 3D-printed HDR surface brachytherapy for basal cell carcinoma in older patients - prospective feasibility and imaging response","","Basal cell carcinoma (BCC) is common in older adults, many of whom are poor candidates for surgery, especially when tumors are on curved and cosmetically sensitive facial sites. This prospective single-arm study evaluated feasibility and 12-month outcomes of personalized 3D-printed HDR surface brachytherapy. Fifteen patients received 51 Gy in 17 fractions using CT-based planning with repeat imaging for fit and reproducibility, and response was assessed clinically and with dermoscopy at 12 months.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/patient-specific-3d-printed-hdr-surface-brachytherapy-for-basal-cell-carcinoma-in-older-patients-prospective-feasibility-and-imaging-response/354281/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/patient-specific-3d-printed-hdr-surface-brachytherapy-for-basal-cell-carcinoma-in-older-patients-prospective-feasibility-and-imaging-response/354281.png","ImageObject",300,407,{"name":92,"@type":93},"Mabel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address for older patients with basal cell carcinoma?","Question",{"text":112,"@type":113},"Many older patients with BCC have poor surgical suitability, particularly for facial tumors where standard flat applicators may not conform well and can worsen dose heterogeneity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the personalized 3D-printed HDR surface brachytherapy delivered and planned?",{"text":117,"@type":113},"Fifteen patients (age ≥65) received HDR surface brachytherapy with custom 3D-printed applicators, delivering 51 Gy in 17 fractions using CT-based planning, with repeat CT imaging to evaluate applicator fit and target coverage.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key 12-month outcomes reported?",{"text":121,"@type":113},"At 12 months, all lesions achieved complete remission with no local recurrence on dermoscopy. Acute skin toxicity was mostly mild, cosmesis was favorable, and quality of life improved based on DLQI scores.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354281,1790734268,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46},7971474920318,"https://ap-avatar.wpscdn.com/avatar/74000ee537e6b0ca360?x-image-process=image/resize,m_fixed,w_180,h_180&k=1788430171632181674","The Oncologist, 2026, 31, oyag206  \n[https://doi.org/10.1093/oncolo/oyag206](https://doi.org/10.1093/oncolo/oyag206)  \n[Published: May 26](Published: May 26), 2026  \nOriginal Article  \n| Patient-specific 3D-printed HDR surface brachytherapy for basal cell carcinoma in older patients: prospective feasibility and imaging response\u003Cbr>Piotr Sobolewski, MD, PhD1,2*, , Mateusz Koper, MD1, Michal Poltorak, MSc, PhD1,\u003Cbr>Pawel Banatkiewicz, MD1, Malgorzata Kolos, MD, PhD1, Lukasz Poltorak, PhD3, Maciej Szwast, PhD4, Irena Walecka, MD, PhD1,2 |  |\n| --- | --- |\n| 1The National Medical Institute of the Ministry of the Interior and Administration, Woloska 137, 02-507 Warsaw, Poland\u003Cbr>2Chair and Clinic of Dermatology and Pediatric Dermatology, Centre of Postgraduate Medical Education, 02-507Warsaw, Poland\u003Cbr>3 Electrochemistry at Soft Interfaces Team, Department of Inorganic and Analytical Chemistry, Faculty of Chemistry, University of Lodz, Tamka 12, 91-403 Lodz, Poland\u003Cbr>4 Department of Chemical and Process Engineering, Warsaw University of Technology, Warynskiego 1, 00-645 Warsaw, Poland\u003Cbr>*Corresponding author: Piotr Sobolewski, MD, PhD, Dermatology Clinic, National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland ([piotr.sobolewski@pimmswia.gov.pl](piotr.sobolewski@pimmswia.gov.pl)) .\u003Cbr>Abstract\u003Cbr>Background: Basal cell carcinoma (BCC) is common in older adults, many of whom are poor surgical candidates, especially for curved and cosmetically sensitive facial sites. High-dose-rate (HDR) surface brachytherapy is effective, but standard flat applicators may fit poorly and increase dose heterogeneity. Patient-specific 3D-printed applicators could improve conformity, yet geriatric BCC data are limited.\u003Cbr>Objective: To assess the feasibility and 12-month outcomes of personalized 3D-printed HDR surface brachytherapy in geriatric patients with BCC.\u003Cbr>Methods: In this prospective single-arm study, 15 patients aged ≥65years with histologically confirmed BCC (predominantly facial) who were unsuitable for surgery received HDR surface brachytherapy using custom 3D-printed applicators. Treatment delivered 51 Gy in 17 fractions with CT-based planning. Repeat CT imaging evaluated applicator fit/reproducibility and target coverage. Acute skin toxicity was graded by RTOG. At 12 months, response was assessed clinically and dermoscopically; cosmesis and quality of life (Dermatology Life Quality Index [DLQI]) were recorded.\u003Cbr>Results: All patients completed treatment. Positioning was highly reproducible (mean setup error \u003C1 mm) with >90% target dose coverage. At 12 months, all lesions achieved complete remission, with no local recurrence on dermoscopy. Acute reactions were mostly mild (73% grade 1), with 13% grade 2 and 13% grade 3; no grade 4 toxicity or serious adverse events occurred. Cosmesis was favorable, and DLQI improved (mean, 10.5 pre-treatment vs 2.9 at 1year; P \u003C .01).\u003Cbr>Conclusions: Personalized 3D-printed HDR surface brachytherapy appears feasible and well tolerated in this small, singlecenter cohort of older patients with BCC, with favorable 1-year local control and quality-of-life improvement when surgery is contraindicated. However, the limited sample size and single-center design represent limitation, and the observed benefit should be regarded as suggestive rather than definitive.\u003Cbr>Key words: geriatric patients; basal cell carcinoma; high-dose brachytherapy; 3D-printed applicator; dermoscopy. |  |\n| Introduction\u003Cbr>Non-melanoma skin cancers (NMSCs), comprising primarily basal cell carcinoma (BCC), represent the most prevalent malignancies worldwide, with a particularly high burden among geriatric patient. The incidence of BCC rises steeply with age due to | cumulative ultraviolet (UV) exposure, immunosenescence, and comorbidities that may impair effective skin repair.1 Although these tumors are typically less aggressive than melanoma, untreated or recurrent lesions can lead to pain and co","cbCaiaaIcT7VJVtz","https://ap.wps.com/l/cbCaiaaIcT7VJVtz","pdf",1277853,"English","# Abstract\n## Background\n## Objective\n## Methods\n## Results\n## Conclusions\n## Key words\n# Implications for Practice","[{\"question\":\"What problem does the study address for older patients with basal cell carcinoma?\",\"answer\":\"Many older patients with BCC have poor surgical suitability, particularly for facial tumors where standard flat applicators may not conform well and can worsen dose heterogeneity.\"},{\"question\":\"How was the personalized 3D-printed HDR surface brachytherapy delivered and planned?\",\"answer\":\"Fifteen patients (age ≥65) received HDR surface brachytherapy with custom 3D-printed applicators, delivering 51 Gy in 17 fractions using CT-based planning, with repeat CT imaging to evaluate applicator fit and target coverage.\"},{\"question\":\"What were the key 12-month outcomes reported?\",\"answer\":\"At 12 months, all lesions achieved complete remission with no local recurrence on dermoscopy. Acute skin toxicity was mostly mild, cosmesis was favorable, and quality of life improved based on DLQI scores.\"}]","Patient-specific 3D-printed HDR surface brachytherapy for basal cell carcinoma in older patients - prospective feasibility and imaging response | PDF",1790109849]